Oragenics Receives European Union CPNP Notifications for ProBiora3® Cosmetic Tablets

TAMPA, Fla.-- Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN), today announced its ProBiora3® tablets intended to freshen breath, whiten teeth and contribute to overall oral health has successfully completed an independent third party review of its Cosmetic Product Safety Report. ProBiora3® is Oragenics’ proprietary blend of probiotics specifically designed for oral care, and is now formulated as a cosmetic mouthwash tablet for use in the European Union. All Oragenics’ independent distributors can now distribute the ProBiora3® tablets in the EU under a Cosmetic designation.

“This cosmetic indication is the first phase in expanding our sales and marketing efforts with our current European partners and will make our ProBiora3®product line even more attractive to additional partnerships. We believe Europeans understand and appreciate the value and health benefits of probiotics,” stated Dr. John N. Bonfiglio, President and CEO, Oragenics, Inc. “We will continue to enhance our European regulatory status as clinical data from our ongoing trials become available.”

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora3® in over 13 countries worldwide.

For more information about Oragenics, visit www.oragenics.com. Follow Oragenics on Facebook and Twitter.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond June 30, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Oragenics, Inc.
Michael Sullivan, 813-286-7900 x246
Chief Financial Officer
Direct: 813-786-6431
msullivan@oragenics.com

Source: Oragenics, Inc.

Released February 11, 2013